Masunaga S, Ono K, Tsutsui K, Abe M
Department of Radiology, Faculty of Medicine, Kyoto University.
Nihon Igaku Hoshasen Gakkai Zasshi. 1990 Feb 25;50(2):139-45.
Ninety patients with glottic and eighteen patients with supraglottic laryngeal cancer (anyN, M0) were treated by conventional fractionation radiotherapy between July, 1963 and August, 1988. Tumor control and cause specific survival were evaluated according to tumor location (glottic or supraglottic) and tumor size (T1, T2, T3, or T4). As a result, the steepness of dose-response curve for the tumor control in T1-2 glottic and T2 supraglottic tumors was more slanting upwards than that in other laryngeal tumors, and the patients whose tumors were irradiated at larger doses had a tendency to survive longer. These results suggested that T1-2 glottic and T2 supraglottic laryngeal tumors can have a good application for hyperfractionation radiotherapy which is a radiation therapy with multiple fractions per day with a small fraction size and with which tumors can receive larger radiation doses than with conventional fractionation radiotherapy. Five patients with glottic or supraglottic tumors treated by hyperfractionation radiotherapy obtained CR, and now show no recurrence. We are going to investigate the usefulness of hyperfractionation radiotherapy after treating more patients with Twice-A-Day fractionation radiotherapy.
1963年7月至1988年8月期间，90例声门型喉癌患者和18例声门上型喉癌患者（任何N，M0）接受了常规分割放疗。根据肿瘤位置（声门型或声门上型）和肿瘤大小（T1、T2、T3或T4）评估肿瘤控制情况和特定病因生存率。结果显示，T1-2声门型肿瘤和T2声门上型肿瘤的肿瘤控制剂量-反应曲线斜率比其他喉癌肿瘤更向上倾斜，且接受较大剂量照射的患者有存活时间更长的趋势。这些结果表明，T1-2声门型和T2声门上型喉癌肿瘤对于超分割放疗可能有良好的应用前景，超分割放疗是一种每天进行多次分割、每次分割剂量较小的放疗方式，与常规分割放疗相比，肿瘤能够接受更大的辐射剂量。5例接受超分割放疗的声门型或声门上型肿瘤患者获得了完全缓解，目前未显示复发。我们将在治疗更多每日两次分割放疗的患者后，研究超分割放疗的有效性。
